Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Authors

Luís Paz-Ares

Published

October 4, 2019

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

The Lancet

Topics

DOI

10.1016/s0140-6736(19)32222-6

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Authors

Luís Paz-Ares

Published

October 4, 2019

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

The Lancet

Topics

DOI

10.1016/s0140-6736(19)32222-6

Paper

Paper

Paper

Paper

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Supporters

Journal

Topics

DOI

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Supporters

Journal

Topics

DOI